Verana Health

CASE STUDY

ALZHEIMER'S ASSOCIATION AAIC 26

Recruitment of Patients with Frontotemporal Dementia Associated with Progranulin Mutations

Presented at the Alzheimer's Association International Conference, 2019

Background

- Frontotemporal dementia (FTD) is a rapidly progressing neurodegenerative disease that is the most common form of dementia for people < 60 years.
- The study is evaluating if the drug of interest will delay the start of symptoms of slow disease progression in patients with the gene mutation.

Methods

Study Therapeutic: A novel therapy for increased progranulin production in GRN+ FTD

Study Type: Phase III Study to evaluate the efficacy and safety of therapeutic

Project Goal: Sponsor is looking to increase efficiency and meet trial enrollment targets.

Results

Verana Health has enabled patient identification at neurology practices in the community, genetic testing and counseling, and trial site referral to accelerate recruitment..

Algorithm Development

2,200

Patients identified with frontotemporal dementia

Site Outreach & Onboarding

10

Practices onboarded for patient identification

Genetic Testing & Counseling

56

Practices referred for genetic testing & counseling